Changsha Sinocare Inc.

Sinocare Inc. is a leading global biosensing technology company specializing in rapid diagnostic test products for chronic disease management, particularly diabetes. Founded in 2002 and headquartered in Changsha, Hunan Province, China, the company ranks #1 in blood glucose meter (BGM) markets in China and #4 worldwide, serving over 25 million users across 187 countries and regions. Sinocare went public in 2011 with 2022 revenues of approximately $248 million. The company develops and manufactures a comprehensive product portfolio including blood glucose meters, test strips, continuous glucose monitoring (CGM) systems, blood pressure monitors, and multiparameter diagnostic devices. Additionally, Sinocare provides hospital diabetes management systems and integrated digital health solutions combining biosensing technology with smart healthcare platforms. With 9 global R&D and manufacturing sites, the company has established substantial international presence through strategic acquisitions including Nipro Diagnostic Inc. and PTS Diagnostics Inc., positioning itself as a comprehensive chronic disease management solution provider for both individual patients and healthcare institutions.